A number of firms have modified their ratings and price targets on shares of Myriad Genetics (NASDAQ: MYGN) recently:
- 10/27/2026 – Myriad Genetics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
- 10/20/2026 – Myriad Genetics was given a new $4.50 price target by Wells Fargo & Company.
- 10/20/2026 – Myriad Genetics was upgraded by Piper Sandler from “underweight” to “neutral”. They now have a $5.00 price target on the stock.
- 10/15/2026 – Myriad Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
- 10/13/2026 – Myriad Genetics had its price target raised by TD Cowen from $4.00 to $4.50. They now have a “hold” rating on the stock.
- 10/12/2026 – Myriad Genetics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 10/2/2026 – Myriad Genetics had its price target raised by Craig Hallum from $4.00 to $8.00. They now have a “buy” rating on the stock.
- 9/9/2026 – Myriad Genetics is now covered by UBS Group. They set a “neutral” rating and a $3.60 price target on the stock.
- 9/1/2026 – Myriad Genetics was downgraded by Piper Sandler from “overweight” to “underweight”. They now have a $2.00 price target on the stock, down from $5.45.
Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company’s testing portfolio spans hereditary cancer, precision oncology, women’s health, mental health and other clinical applications.
Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.
Featured Stories
- Five stocks we like better than Myriad Genetics
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Myriad Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
